You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Around the Region

Equity firm buys 6.2% stake in Ariad

Private investment firm Sarissa Capital Management of Greenwich, Conn., has taken a 6.2 percent stake in Cambridge-based Ariad Pharmaceuticals Inc. and plans to seek representation on the drug maker’s board, according to a regulatory filing Tuesday.

The filing with the Securities and Exchange Commission said representatives of Sarissa — founded by chief investment officer Alexander J. Denner, a protege of activist investor Carl Icahn — recently contacted Ariad and “requested a dialogue” with management and the board. Investment firm executives “reserve the right to take whatever future action they deem appropriate,” including buying additional shares, the filing said.

Continue reading below

Ariad has suffered a sharp drop in its market value in recent weeks amid new safety questions about its leukemia drug Iclusig. The company canceled a clinical trial aimed at expanding the number of patients eligible to take the medicine and put a hold on plans to move into a new headquarters and lab complex in Kendall Square.

Robert Weisman can be reached at Follow him on Twitter @GlobeRobW.
Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of